Streetbeat News

Products Services

EDSA

Edesa Biotech, Inc. (NASDAQ:EDSA) announced positive findings from an in vitro study of its monoclonal antibody candidate, paridiprubart, against a panel of respiratory pathogens. The study was completed by the University of Toronto in parallel to the company's ongoing clinical study of EB05 (paridiprubart) in hospitalized Covid-19 patients with Acute Respiratory Distress Syndrome (ARDS).

Portfolio Pulse from Benzinga Newsdesk

June 28, 2023 | 11:57 am

BABA

NVDA

Alibaba's stock is trading lower due to reports of the U.S. adopting a stricter stance over China's AI ambitions. The U.S. plans to revise export controls on AI chips to limit China's access to advanced technologies with military applications. Alibaba recently revealed its large language model (LLM), Tongyi Qianwen, and plans to incorporate it across various businesses. Alibaba's fintech affiliate Ant Group is developing large-language model technology to power ChatGPT-style services. Nvidia bagged significant orders from major Chinese internet companies, including Alibaba.

Portfolio Pulse from Anusuya Lahiri

June 28, 2023 | 11:53 am

SSNLF

TSM

Samsung has announced plans to begin mass production of 2 nanometer process for mobile applications in 2025. This is part of Samsung's roadmap to catch up to Taiwan Semiconductor Manufacturing Company (TSMC).

Portfolio Pulse from Benzinga Newsdesk

June 28, 2023 | 11:49 am

RETA

Reata Pharmaceuticals' shares are trading higher following the FDA's approval of a Prior Approval Supplement to update Skyclarys (Omaveloxolone) Drug Substance Specification for Friedreich's Ataxia in adults and adolescents.

Portfolio Pulse from Benzinga Newsdesk

June 28, 2023 | 11:45 am

ZVSA

ZyVersa Therapeutics has announced a publication in Clinical Immunology that demonstrates a link between renal NLRP3 inflammasome activation and Lupus Nephritis disease activity. The company is developing Inflammasome ASC Inhibitor IC 100, which can inhibit up to 12 different inflammasomes, including NLRP3 inflammasomes.

Portfolio Pulse from Bill Haddad

June 28, 2023 | 11:39 am

OPK

PFE

The FDA has approved the NGENLA (somatrogon-ghla) treatment for pediatric growth hormone deficiency, a partnership product of Opko Health and Pfizer. This has led to a rise in Opko Health's shares.

Portfolio Pulse from Benzinga Newsdesk

June 28, 2023 | 11:38 am

AVXL

Anavex Life Sciences has announced long-term clinical study results for ANAVEX 2-73-RS-001, showing disease modifying effects in Rett Syndrome. The results could potentially lead to a new treatment for the disease.

Portfolio Pulse from Bill Haddad

June 28, 2023 | 11:37 am

ZLAB

Zai Lab has announced that China's National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for Repotrectinib for patients with ROS1-Positive NSCLC. This is a significant step for Zai Lab in their efforts to bring this drug to market.

Portfolio Pulse from Bill Haddad

June 28, 2023 | 11:34 am

AMST

Amesite Inc. (AMST) has announced that its V6.3 update will be available to customers starting July 10.

Portfolio Pulse from Bill Haddad

June 28, 2023 | 11:33 am

BEST

BEST Inc. has integrated the natural language processing tool ChatGPT into its Qianyi ERP software. This allows cross-border sellers to generate multi-language product titles and descriptions using AI. The company plans to launch automatic pricing, processing of product images, and automatic generation of posters soon. The software supports Chinese, English, Thai, Vietnamese, and Indonesian languages. BEST shares are trading higher by 7.9% to $2.30 in the premarket session.

Portfolio Pulse from Nabaparna Bhattacharya

June 28, 2023 | 11:19 am